Cardiome Pharma Corp.

Emory University

Imperial College of Science, Technology and Medicine

Other

Hoffman/barrett, L.l.c.

Imperial College of London

Anthony G M Barrett

Bertrand M C Plouvier

Doug Ta Hung Chou

Tao Sheng

Grace Jung

Lewis Siu Leung Choi

Pirmin Ulmann

Alfred Hedinger

Marco Silvio Passafaro

Martin Kurz

Daniel Moeckli

Dennis C Liotta

James P Snyder

Jeff Jiqun Zhu

Yuzhong Liu

Robin D G Cooper

Ashutosh S Jogalekar

Matthew John Fuchter

Bodo Scheiper

Simak Ali

Brian M Hoffman

Matthew J Cook

Sebastian H B Kroll

Raoul Charles Dalmedo Stuart Coombes

Aleksandra Siwicka

Jan Brackow

Evan R Trivedi

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.

Synthetic process for aminocyclohexyl ether compounds

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed. 

Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation.

Porphyrazine optical and dual optical/MR contrast and therapeutic agents

Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-&#x3b1;]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-&#x3b1;]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.

Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds

Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Aminocyclohexyl ether compounds and uses thereof

This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.

Selective inhibitors for cyclin-dependent kinases

The present invention relates to novel intermediates for the preparation of 3-methylenecephams of the formula IIA.wherein:

Compounds and method for preparing 3-methylcephams

Intermediates for and synthesis of 3-methylene cephams

Growing community of inventors

London, United Kingdom

Anthony G M Barrett